PURPOSE: The epidermal growth factor receptor (EGFR) is one of the four human epidermal receptors. The efficacy and safety of EGFR-targeted therapies for treating non-small-cell lung cancer (NSCLC) remained controversial. The aim of this study was to systematically evaluate EGFR-targeted therapies plus chemotherapy for advanced NSCLC. METHODS: Cochrane Central Register of Controlled Trials, PubMed, and Embase were searched for relevant studies. Quantitative analysis was carried out to evaluate survival, response, and toxicity of EGFR-targeted therapies. RESULTS: Ten randomized controlled trials (RCTs) involving 5,936 patients were identified out of 107 studies. There was no statistical difference in overall (OS) and 1-year (OYS) survival rate when small-molecule tyrosine kinase inhibitors (TKIs) plus platinum-based doublet chemotherapy (PBDC) were compared with PBDC alone. However, progression-free survival [hazard ratio (HR)=0.87, 95% confidence interval (CI) 0.76-0.99] and overall response rate (ORR) were marginally improved. Prolonged OS (HR=0.87, 95% CI 0.78-0.96) and increased ORR and OYS were found when cetuximab plus PBDC was compared with PBDC alone. Adverse events in the combination arms were similar in incidence to those of the chemotherapy-alone arms, with the exception of an increased incidence of rash and diarrhea. CONCLUSIONS: Cetuximab adds benefits to NSCLC patients compared with PBDC alone. Small-molecule TKIs plus PBDC lead to a slightly additive efficacy compared with PBDC alone.
PURPOSE: The epidermal growth factor receptor (EGFR) is one of the four human epidermal receptors. The efficacy and safety of EGFR-targeted therapies for treating non-small-cell lung cancer (NSCLC) remained controversial. The aim of this study was to systematically evaluate EGFR-targeted therapies plus chemotherapy for advanced NSCLC. METHODS: Cochrane Central Register of Controlled Trials, PubMed, and Embase were searched for relevant studies. Quantitative analysis was carried out to evaluate survival, response, and toxicity of EGFR-targeted therapies. RESULTS: Ten randomized controlled trials (RCTs) involving 5,936 patients were identified out of 107 studies. There was no statistical difference in overall (OS) and 1-year (OYS) survival rate when small-molecule tyrosine kinase inhibitors (TKIs) plus platinum-based doublet chemotherapy (PBDC) were compared with PBDC alone. However, progression-free survival [hazard ratio (HR)=0.87, 95% confidence interval (CI) 0.76-0.99] and overall response rate (ORR) were marginally improved. Prolonged OS (HR=0.87, 95% CI 0.78-0.96) and increased ORR and OYS were found when cetuximab plus PBDC was compared with PBDC alone. Adverse events in the combination arms were similar in incidence to those of the chemotherapy-alone arms, with the exception of an increased incidence of rash and diarrhea. CONCLUSIONS:Cetuximab adds benefits to NSCLCpatients compared with PBDC alone. Small-molecule TKIs plus PBDC lead to a slightly additive efficacy compared with PBDC alone.
Authors: Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544
Authors: Chia-Hsuin Chang; Kuan-Yu Chen; Yinong Young-Xu; Tobias Kurth; E John Orav; Pan-Chyr Yang; K Arnold Chan Journal: Lung Cancer Date: 2008-04-18 Impact factor: 5.705
Authors: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: R Rosell; G Robinet; A Szczesna; R Ramlau; M Constenla; B C Mennecier; W Pfeifer; K J O'Byrne; T Welte; R Kolb; R Pirker; A Chemaissani; M Perol; M R Ranson; P A Ellis; K Pilz; M Reck Journal: Ann Oncol Date: 2007-10-17 Impact factor: 32.976
Authors: Ulrich Gatzemeier; Anna Pluzanska; Aleksandra Szczesna; Eckhard Kaukel; Jaromir Roubec; Flavio De Rosa; Janusz Milanowski; Hanna Karnicka-Mlodkowski; Milos Pesek; Piotr Serwatowski; Rodryg Ramlau; Terezie Janaskova; Johan Vansteenkiste; Janos Strausz; Georgy Moiseevich Manikhas; Joachim Von Pawel Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: John V Heymach; Luis Paz-Ares; Filippo De Braud; Martin Sebastian; David J Stewart; Wilfried E E Eberhardt; Anantbhushan A Ranade; Graham Cohen; Jose Manuel Trigo; Alan B Sandler; Philip D Bonomi; Roy S Herbst; Annetta D Krebs; James Vasselli; Bruce E Johnson Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: J Bachmann; T Müller; A Schröder; C Riediger; M Feith; D Reim; H Friess; M E Martignoni Journal: Med Oncol Date: 2015-06-13 Impact factor: 3.064
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Manjula Nakka; Donald A Barkauskas; Mark Krailo; Lisa L Wang; Laszlo Perlaky; Ching C Lau; M John Hicks; Tsz-Kwong Man Journal: Cancer Date: 2016-08-16 Impact factor: 6.860
Authors: David F Heigener; José Rodrigues Pereira; Enriqueta Felip; Juraj Mazal; Lyudmila Manzyuk; Eng Huat Tan; Ofer Merimsky; Barbara Sarholz; Regina Esser; Ulrich Gatzemeier Journal: Target Oncol Date: 2014-09-09 Impact factor: 4.493
Authors: Mark A Socinski; Tracey Evans; Scott Gettinger; Thomas A Hensing; Lecia VanDam Sequist; Belinda Ireland; Thomas E Stinchcombe Journal: Chest Date: 2013-05 Impact factor: 9.410